Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai’s Q1 Earnings Brisk on Hemlibra, Oncology Franchise
April 24, 2020
- Life Science Institute’s Muse Cell Product Shows Safety, Tolerability in 2 Trials
April 24, 2020
- Biogen Delays US Aducanumab Filing to Q3, but Keeps Japan’s 2020 Plan Intact
April 24, 2020
- CMIC Group to Support Clinical Trial, Manufacturing of Avigan for COVID-19 Treatment
April 24, 2020
- Kyorin’s Coronavirus Detection Reagent Now Available
April 24, 2020
- Relugolix Combo Improves Endometriosis, Non-Menstrual Pelvic Pain in PIII: Myovant
April 24, 2020
- Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
April 23, 2020
- World’s 1st Topical JAK Inhibitor to Hit Shelves on June 24: JT/Torii
April 23, 2020
- Nichi-Iko Recall Hits Towa’s Teprenone Supply
April 23, 2020
- Pfizer Japan Further Extends Work-from-Home through May-End
April 23, 2020
- Remicade Biosimilars OK’ed for Behcet’s-Associated Uveitis
April 23, 2020
- Ube Industries to Start Avigan Intermediate Supplies from July
April 23, 2020
- Myovant Files Relugolix for Advanced Prostate Cancer in US
April 23, 2020
- JCR to Develop 2 Mucopolysaccharidosis Drugs Using BBB-Penetrating Technology
April 23, 2020
- Japan Heading into Earnings Season amid Coronavirus Woes
April 22, 2020
- Shin Nippon Biomedical Joins AnGes Vaccine Development
April 22, 2020
- Drug Makers Restricting Nafamostat Supplies as Hopes Grow for Its Repurposing for COVID-19
April 22, 2020
- Ehime Univ., Sumitomo Dainippon Decipher Mechanism of Action of Malaria Vaccine Candidate
April 22, 2020
- Positive Data in Hand, Ono/Takeda to Seek 1st-Line RCC Nod for Opdivo/Cabometyx Combo
April 22, 2020
- Astellas Scoops Up UK's Mitochondria-Focused Biotech Nanna
April 22, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…